Passage Bio, Inc. - Common Stock (PASG)

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

PASG stock results show that Passage Bio beat analyst estimates for earnings per share the second quarter of 2024.

It's time to dive into the biggest pre-market stock movers as we check out all of the latest news worth reading about on Tuesday morning!

PASG stock results show that Passage Bio beat analyst estimates for earnings per share the first quarter of 2024.

PASG stock results show that Passage Bio beat analyst estimates for earnings per share the fourth quarter of 2023.

Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot.

Although nano-cap stocks are super-risky just like stealing bases in baseball, there may be a time and place for extreme speculation.

Shares of BlackBerry Limited (NYSE: BB) moved lower in pre-market trading following the release of third-quarter results.

Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for frontotemporal dementia (FTD) with 

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page